AKT1 and cancer: Notably, Kaempferol 3‐rutinoside‐4′‐glucoside and Kaempferol 3‐rutinoside‐7‐sophoroside exhibited substantially higher binding affinities compared to Ipatasertib, presenting innovative therapeutic candidates for the treatment of Akt1‐driven cancers.